Patents-Review.com
ClassID:

97107 ⎘

C07K16/085 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus

Sub-classes:
Recent Application in this class:
#1
20250262242
2025-08-21

HUMAN T CELL RECEPTORS SPECIFIC FOR ANTIGENIC PEPTIDES DERIVED FROM MITOGEN-ACTIVATED PROTEIN KINASE 8 INTERACTING PROTEIN 2 (MAPK8IP2), EPSTEIN-BARR VIRUS OR HUMAN ENDOGENOUS RETROVIRUS, AND USES THEREOF

 #2
20250101125
2025-03-27

METHODS FOR OBTAINING ANTIBODY MOLECULES BINDING TO A PEPTIDE-MHC INTERFACE

 #3
20240409589
2024-12-12

MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES

 #4
20240408195
2024-12-12

EPSTEIN-BARR VIRUS VACCINES

 #5
20240390706
2024-11-28

ANTIBODIES AND METHODS FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION

 #6
20240360184
2024-10-31

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

 #7
20240358813
2024-10-31

Multivalent Epstein-Barr virus-like particles and uses thereof

 #8
20240325539
2024-10-03

METHODS AND COMPOSITIONS FOR TREATING EPSTEIN BARR VIRUS-ASSOCIATED CANCER

 #9
20240309451
2024-09-19

DIAGNOSTICS AND THERAPEUTICS FOR EBV IN MS AND OTHER AUTOIMMUNE DISEASES

 #10
20240309071
2024-09-19

Inverse Agonistic Anti-US28 Antibodies

 #11
20240174735
2024-05-30

ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION

 #12
20240123059
2024-04-18

Kaposi's Sarcoma Associated Herpesvirus Vaccine and Methods of Making and Using Thereof

 #13
20240123058
2024-04-18

EPITOPE PEPTIDE AND ANTIBODY FOR PREVENTING AND TREATING EB VIRUS INFECTION AND RELATED DISEASES

 #14
20240052013
2024-02-15

SYSTEMS AND METHODS TO LINK CD40 SIGNALING TO ANTIGEN BINDING

 #15
20230348568
2023-11-02

EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF

 #16
20230295273
2023-09-21

METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS

 #17
20230293673
2023-09-21

METHODS FOR TREATING AND PREVENTING CYTOMEGALOVIRUS INFECTION

 #18
20230250159
2023-08-10

SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES

 #19
20230181639
2023-06-15

T CELL ANTIGEN RECEPTOR, MULTIMERIC COMPLEX THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF

 #20
20230167178
2023-06-01

Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof

 #21
20230159626
2023-05-25

EPSTEIN-BARR VIRUS ANTIBODIES AND USES THEREOF

 #22
20230056712
2023-02-23

Epstein-Barr virus antibodies and uses thereof

 #23
20220306701
2022-09-29

MHC class I epitope delivering polypeptides

 #24
20220275030
2022-09-01

De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals

 #25
20220160762
2022-05-26

ENGINEERED IMMUNE CELLS

 #26
20220098284
2022-03-31

Antibodies and methods for the diagnosis and treatment of Epstein Barr Virus infection

 #27
20220056101
2022-02-24

Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers

 #28
20220000085
2022-01-06

MANIPULATION OF IMMUNOGLOBULIN GENE DIVERSITY AND MULTI-ANTIBODY THERAPEUTICS

 #29
20210253648
2021-08-19

MHC class I epitope delivering polypeptides

 #30
20210205465
2021-07-08

ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY

 #31
20210198344
2021-07-01

Systems and methods to produce B cells genetically modified to express selected antibodies

 #32
20210171610
2021-06-10

Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection

 #33
20210115113
2021-04-22

EPSTEIN-BARR VIRUS ANTIBODIES AND USES THEREOF

 #34
20210095021
2021-04-01

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

 #35
20210032316
2021-02-04

Inverse agonistic anti-US28 antibodies

 #36
20210017512
2021-01-21

CELL-TARGETING MOLECULES COMPRISING PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CARBOXY-TERMINAL MOIETIES

 #37
20200330587
2020-10-22

Epstein-barr virus vaccines

 #38
20200276295
2020-09-03

Multivalent Epstein-Barr virus-like particles and uses thereof

 #39
20200255499
2020-08-13

Antibody to Epstein Barr Virus and Uses Thereof

 #40
20200207873
2020-07-02

Antibodies and peptides to treat HCMV related diseases

 #41
20200190168
2020-06-18

Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

 #42
20200164059
2020-05-28

Epstein Barr virus antibodies, vaccines, and uses of the same

 #43
20200115470
2020-04-16

T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA

 #44
20200110088
2020-04-09

Diagnosis and treatment of viral diseases

 #45
20200055924
2020-02-20

Epstein-Barr virus antibodies and uses thereof

 #46
20200002387
2020-01-02

CD20-BINDING IMMUNOTOXINS FOR INDUCING CELLULAR INTERNALIZATION AND METHODS USING SAME

 #47
20190375827
2019-12-12

Compositions containing anti-HIV ostrich antibodies

 #48
20190358317
2019-11-28

Cytomegalovirus surface protein complex for use in vaccines and as a drug target

 #49
20190153044
2019-05-23

MHC Class I Epitope Delivering Polypeptides

 #50
20190016788
2019-01-17

Antibody and antibody-containing composition

 #51
20180318418
2018-11-08

Anti-BARF1 monoclonal antibody

 #52
20180258187
2018-09-13

T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA

 #53
20180258144
2018-09-13

CYTOTOXIC PROTEINS COMPRISING CELL-TARGETING BINDING REGIONS AND SHIGA TOXIN A SUBUNIT REGIONS FOR SELECTIVE KILLING OF SPECIFIC CELL TYPES

 #54
20180237520
2018-08-23

Method for generating antibodies against T cell receptor

 #55
20180180615
2018-06-28

Diagnosis and treatment of viral diseases

 #56
20180155423
2018-06-07

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

 #57
20180154013
2018-06-07

ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY

 #58
20180066042
2018-03-08

Antibody and antibody-containing composition

 #59
20180030121
2018-02-01

ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE

 #60
20180008695
2018-01-11

THERAPEUTIC VACCINES FOR TREATING HERPES SIMPLEX VIRUS TYPE-2 INFECTIONS

 #61
20170189517
2017-07-06

Antigenic epitopes from EBV gp350/220 and uses thereof

 #62
20170168053
2017-06-15

Diagnosis and treatment of viral diseases

 #63
20170101636
2017-04-13

Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties

 #64
20160340416
2016-11-24

Antibody and antibody-containing composition

 #65
20160340394
2016-11-24

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

 #66
20160303224
2016-10-20

Epstein-Barr virus vaccines

 #67
20160177284
2016-06-23

CELL-TARGETED MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS

 #68
20160017047
2016-01-21

CD20-binding immunotoxins for inducing cellular internalization and methods using same

 #69
20160017038
2016-01-21

Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof

 #70
20150344976
2015-12-03

Diagnosis and treatment of viral diseases

 #71
20150064174
2015-03-05

Neutralizing antibody for epstein barr virus-associated disease

 #72
20150056198
2015-02-26

Aberrant cell-restricted immunoglobulins provided with a toxic moiety

 #73
20140370026
2014-12-18

Cytomegalovirus Surface Protein Complex For Use in Vaccines and as a Drug Target

 #74
20140349880
2014-11-27

Antibiotic preparation method and platform system based on same

 #75
20140342349
2014-11-20

Use of at least one biomarker for the in vitro prognosis or diagnosis of lymphoproliferative episodes associated with the Epstein-Barr virus (EBV)

 #76
20140296492
2014-10-02

HLA-restricted, peptide-specific antigen binding proteins

 #77
20140234337
2014-08-21

ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION

 #78
20140212416
2014-07-31

Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics

 #79
20140193483
2014-07-10

Therapeutic vaccines for treating herpes simplex virus type-2 infections

 #80
20140093526
2014-04-03

Preparation of Neutralizing Antibody to Human Herpesvirus 6 Glycoprotein Q1 and Analysis Thereof

 #81
20140037623
2014-02-06

Pharmaceutical Compositions Comprising Antibodies Binding To EBV (Ebstein-Barr Virus) Protein BARF1

 #82
20140024809
2014-01-23

HLA-restricted, peptide-specific antigen binding proteins

 #83
20130143316
2013-06-06

Nucleic acids molecule encoding the polypeptide for treating virus-induced cancer

 #84
20130143268
2013-06-06

Method of producing the polypeptide for treating virus-induced cancer

 #85
20130142797
2013-06-06

Method of treating virus-induced cancer

 #86
20130066051
2013-03-14

Fusion polypeptide against EB virus-induced tumor and colicin Ia mutant

 #87
20120294874
2012-11-22

Method for Producing T Cell Receptor-Like Monoclonal Antibodies and Uses Thereof

 #88
20120270292
2012-10-25

Photo-Inactivated Viruses and Systems and Methods of Using the Same

 #89
20120226023
2012-09-06

Cytomegalovirus surface protein complex for use in vaccines and as a drug target

 #90
20120195856
2012-08-02

Method of treating patients with cardiovascular illness

 #91
20120165512
2012-06-28

Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases

 #92
20120107319
2012-05-03

Pharmaceutical compositions comprising antibodies binding to the intracellular domain of EBV (Epstein-Barr virus) latent membrane protein-1 (LMP1)

 #93
20110200633
2011-08-18

Cytomegalovirus surface protein complex for use in vaccines and as a drug target

 #94
20110135642
2011-06-09

Pharmaceutical Compositions Comprising Antibodies Binding To EBV (Ebstein-Barr Virus) Protein BARF1

 #95
20110064759
2011-03-17

Extracellular domains of Epstein Barr Virus (EBV) tumor-associated latent membrane proteins

 #96
20080260687
2008-10-23

SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY

 #97
20080187545
2008-08-07

Cytomegalovirus surface protein complex for use in vaccines and as a drug target

 #98
20080175849
2008-07-24

Immunoreactive peptides from Epstein-Barr virus

 #99
20080075717
2008-03-27

Antigen imitating extracellular areas of membrane proteins of type III produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof

 #100
20080069819
2008-03-20

Method and composition for detecting cancer by means of detection of Epstein-Barr virus nuclear antigen 2 coactivator P100

 #101
20070243162
2007-10-18

Specific binding agents for KSHV vIL-6 that neutralize a biological activity

 #102
20070015197
2007-01-18

Specific binding agents for KSHV vIL-6 that neutralize a biological activity

 #103
20060257428
2006-11-16

Assays and therapies for latent viral infection

 #104
20060257427
2006-11-16

Assays and therapies for latent viral infection

 #105
20060233813
2006-10-19

Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith

 #106
20060193867
2006-08-31

Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith

 #107
20060068442
2006-03-30

Epstein Barr Virus (EBV) tumor-associated latent membrane extracellular domain peptides

 #108
20060039927
2006-02-23

Specific binding agents for KSHV vIL-6 that neutralize a biological activity

 #109
20050239052
2005-10-27

Cloning of rhadinovirus genome and methods for its use

 #110
20050129701
2005-06-16

Antibody to latent membrane proteins and uses thereof

 #111
20050074751
2005-04-07

Assays and therapies for latent viral infection

 #112
20050074749
2005-04-07

Method for the identification of extracellular domains of the epstein barr virus (ebv), tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith

 #113
12573636
2017-05-23

Method for treating or preventing mood disorders